MedTrace Logo

Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp

NCT02838628 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2021-04-14

Study results available
· View outcomes & findings →

Summary

In this study, the activity, safety, and pharmacokinetics (PK) of KX2-391 Ointment was evaluated in adult participants with a clinical diagnosis of stable, clinically typical actinic keratosis (AK) on the face or scalp.

Conditions

  • Actinic Keratosis

Interventions

DRUG

50 mg of KX2-391 Ointment 1%

Dose: 50 mg; Route of administration: Topical

DRUG

50 mg of KX2-391 Ointment 1%

Dose: 50 mg; Route of administration: Topical

Sponsors & Collaborators

  • Athenex, Inc.

    collaborator INDUSTRY

  • Almirall, S.A.

    lead INDUSTRY

Principal Investigators

  • Jane Fang, MD · Kinex Pharmaceuticals Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-11
Primary Completion
2017-01-11
Completion
2017-12-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02838628 on ClinicalTrials.gov